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The findings in 3,256 consecutive patients hospitalized for acute
myocardial infarction were tabulated to assess the history, treat-
ments and outcome in the elderly ; 1,848 patients (569 I sere
>65 years of age, including 28% who were aged >75 years . The
incidence of prior angina, hypertension and heart failure lonly 3%
of patients <55 years of age had a history of heart failure
compared with 24% >75 years old) was found to increase with
age. Twenty-nine percent of patients <75 years of age were
treated with a systemic thrombolytic drug compared with only 5
1,
of patients older than 75 years .
Mortality rates increased strikingly with advanced age (<2e1
in patients <-55, 4 .69 in those 55 to 64, 12.31, in those 65 to 74
and 17.8% in those >75 years)
. Both the incidence of complicating
illness and a uondiagnostic electrocardiogram IECGI increased
Several trials (1-4) have shown that Ihrombolvtic therapy
reduces mortality in selected patients with suspected Acute
myocardial infarction and that it may have its greatest effect
in patients >78 years of age
. However. either by protocol
design or perhaps because of the higher prevalence of
complicating coexisting conditions in older patients C$ .bl .
only a small proportion of patients in these clinical trials
have been elderly . There is also general concern about an
increased risk of bleeding complications in elderly patients.
i n particular intracerebral hemorrhage . which has been re-
ported to be higher in the setting of advanced age, a high
dose of the thrombolytic agent in relation to body weight and
a history of prior cercbrovascular disease 17-IU) . although
none of these factors is helpful in determining risk for
individual patients .
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with age . In a multivariate analysis of outcome in older patients
(-65 years), adverse events were related to both prior history of
heart failure (odds ratio 3 .9) and increasing age (odds ratio 1 .4 per
each decade of age)
.
Outcome-mat improved by treatment with
thrombolytic drugs, but these agents were prescribed to only 12°r
of patients >65 years of age, thereby reducing the power fur
detecting such an effect.
'these findings show that the elderly frequently develop acute
infarction in the setting of prior complications from isehemic heart
disease and have an extremely high hospital mortality rate ; the
drsision to treat these patients is hampered by their higher
incidence of complicating illness, absence of chest pain on admis-
sion and nonspecific ECG abnormalities .
(J Am Call Cardiol 1991 ;18:657-62)
The objective of this study is to characterioe or'IVrail the
distribution of patients hospitalized for acute myocardial
infarction and to describe the coexisting illnesses, treatment
and outcome according to age. Unlike observations from
previous trials (1-41 . the findings are from unselected pa-
tients admitted to every coronary care unit in the greater
metropolitan Seattle area .
Methods
Study patients. The Myocardial Infarction . Triage and
Inlervealion IMITI) Project is a clinical trial in a registry of
patients with acute myocardial infarction admitted to all 19
coronary'_ re units in the greater metropolitan Seattle area .
A detailed description of this project has been reported
i,reviously (11). Briefly, the trial will compare results
achieved when patients receive very early thrombolytic
treatment administered by paramedics with Ihose achieved
when treatment is initiated in the hospital emergency depart-
neat.
All patients with suspected pain of cardiac origin are
screened for possible inclusion in the trial and an electrocar-
diogram IECG) is obtained
. In addition to the clinical trial . a
registry of Patients with acule infarction has been estab-
lished . The admitting diagnoses for ail patients presenting to
all coronary care units in the greater metropolitan Seattle
all, -7 11 'Ma
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Table I . ('finical Characleriaie • 43216 Patients by Age Strata
Age
'p raluc, arc for chi-square tests xilh 3 degrees of freedom .
area are screened to detect patients with suspected myocar-
dial infarction . Hospital medical records arc then abstracted .
For how patients with evidence of acute myocardialinfarc-
tion
l
patient demographics, prior cardiac history, hospital
treatment, complications and outcome are recorded
. The
treatment provided to these patients . with the exception of
the small proportion in the clinical trial, is that prescribed by
the patient's physician and not that of any specific protocol .
The project was approved in 1988 by the University of
Washington as well its the Human Subjects Review Commit-
tee of the individual hospitals .
Statistical analysis. Discrete variables were analyzed by
contingency analysis and continuous variables by using
analysis of variance. Logistic regression analyses were done
to adjust for the effect of multiple variables on outcome in
the subset of patients >65 years of age .
Results
Patient characteristics (Table 1) . The findings in 3,256
consecutive patients hospitalized during 1988 and early 1989
who had a discharge diagnosis of acute myocardial infarction
were tabulated . Figure I shows the distribution of patients
by „gc : 662 patients (20%) were <55, 746 !23%I were 55 to
64
. 925 (28%1 were 65 to 74 and 923 (2890) were 075 years
of age . Although only 17% of patients <55 years of age
were women . 567 of those >75 years were women . The
Figure I
. Ace and gender distriburinn of 3,256 patients with evi-
dence of acute myocardial infarction treated at 19 greater meoopol-
iran Seattle area hospiuds
: 571 of patients were >65 years of age .
including 2_851 who were >_75 years .
Age 150013
.1
\member
IYathp-u!
incdence of a prior history of angina, hypertension . myo-
carcialinfarction and . .nost notably. congestive heart failure
incre -'I with age. Only 3% of patients <55 years of age had
a history of heart failure before hospital admission for acute
infarction, whereas 247c of those >75 years had this finding
(p < 0 .001311
.
Figure 2 shows that older patients delay longer from chest
pain onset until hospital admission . Although the median
time delay (approximately 2 hl to hospital admission was
similar for all age groups, the average delay increased
substantially with increasing age; 4 .1 h in patients <55, 5 .2 h
in those 55 to 64 . 5 .1 h in those 65 to 74 and 6.1 h in patients
075 years . of whom 24% came to the hospital >6 h after
symptom onset (p < 0
.01) .
Treatment delivered and clinical findings
(Table
2) . There
was a marked inverse relation between the proportion
treated with thrombolytic drugs and increasing age . Overall,
29% of patients <75 years of age were treated with intrave-
nous thrombolytic drugs compared with only 5% of patients
older than this age . Despite the higher incidence of poten-
tially complicating illness and the subsequent low rate of use
of thrombolytic therapy, alternative treatment by emergency
Figure 2 . Interval from chest pain onset until hospital admission by
age strata . Box and whisker plots and the median time delay arc
shown
. The box represents 25 in 7-- percentiles and the limits
represent 2 .5 times the box or the 5th and 95th percentiles . Although
the median delay increased slightly with age . the mean delay from
chest pain onset until hospital admission (nut shownt increased
substantially from 4 .1 * 8 h for patients
<55
years to 6.1 ± I I t h
in patients 05 years .
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coronary angiography or direct angiopla,ty ss
as also per-
formed less frequently fin 54 of patients <75 gears of age
within the first 12 h of admission compared with 2'_
; of
those <75 years old) Ip < 0.001) . Ecen other recognized
medical treatment for acute myocardial infarction (for exam-
ple, aspirin and beta-adrenereic blocking agents) was pre-
scribed substantially less often in older patients . Either or
both of these drugs were used in 67% of the older versus 1t&'i
of the younger patients (p < 0.0001) .
It was not possible to accurately ascertain the proportion
of the entire cohort of patients with acute myocardial in-
farction who had findings that would normally he used to
select those for treatment with thrombolytic therapy . How-
ever . these potential inclusion and exclusion criteria could
be ascertained in the subset of patients (4041 who were
initially evaluated and transported by paramedics . In this
subset, paramedics prospectively tabulated each of the
conditions as they screened patients for possible prehos-
pital administration of thrombolytic therapy . Figure 3 shows
Figure 3. Characterization of patients transported by paramedic, .
Shown are the proportions of patients with acute myocardial infer,
lion in each age strata in whom there w no potential risks for
treatment with thrombolytic therapy . The influence of the absence
ofchest pain, coexisting illness associated with an increased risk of
hemorrhage and the proportion coming to the hospital -6 h after
symptom onset is evident
. Electnrcardiographic I ECGI linings are
not considered, although in a subset . 63'i of those <55 years and
54) -75 years had Sf elevation on the admitting ECG . The
incidence of each of these confounding factor, was grctdesl in
elderly patients .
'p ,1u, ,re to chi-,q,,re lo, vi h ' dc,-" rd inanity- gcnnrmN ruthm
C h of ho•puai euml,•u,n-
13 Chest PM, Absent
O a10 w, 05501,9
® noisy a a hours
O Pammlni Candldstc
the proportion of patients in each age stratum meeting
criteria for treatment with thrombolytic therapy
. exclusive
of the initial ECG abnormality
. Although more elderly
patients came to the hospital late . late presentation did not
contribute greatly as a potential exclusion criterion . The
proportion of patients with findings associated with a higher
risk of serious bleeding increased with age (present in
2_I'i of
the group -:iS pears of age compared with 284 in those
>75 searst (p - 0 .02): the proportion without symptoms of
chest discomfort increased from 249 to 41 1:i, respectively
I p < 0 .0(1(11 1.
In all . 5 ri of those patients with acute infarction
,55 scars of age compared with 2651 of those -75 years old
had findings suitable for consideration for treatment with
thrombolytic drugs . These findings included ongoing chest
pain if <6-h duration and absence of risk factors for
potentiaik serious hemorrhage, severe hypertension (systol-
ic blood pressure >180 mm Hg and diastolic blood pressure
> 1211 mm Hg) and prior history of stroke . recent surgery.
trauma or confounding illness (p < 0
.0011 . These proportions
arc independent of the finding of ST elevation, which also
currently infleences patient selection. To measure the mdu-
ence of this effect on treatment, it was determined in a
random subset of 100 patients <55 years of age that 634 had
ST elevation compared with only 54:0 in a similar group
o75 (ears old (p < 0.05) . Thus, assuming that these data are
representative of all patients with acute infarction . -15% of
patients -75 years of age would he suitable candidates for
consideration of thrombolytic drug treatment .
In-hospital cardiac events (Table 3)
. Unexpected cardiac
arrest occurred significantly less often in older than in
younger pmients
; 4 .1 J of patients <55 years of age had a
cardiac arrest compared with only 12% of patients
a75 years old (p
-
0.001)
. Evidence of new heart failure was
recorded in 19% of patients <65 years of age versus 3154 of
patients -65 years old (p < ^ .(0101) .
The inc idrsre of (troke also increased substanlittllr raids
q¢e . Only 1 .4% of patients <55 years of age developed a
stroke in the hospital, compared with 3
.955 of patients
-'75 sears old Ip
- 11.11)0)4) . The incidence of reinfarction
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-p value . arc far cIli-wuare I"V, rcith 3 degree of freedom .
before hospital discharge was twice as great in the elderly
group (5 .57 vs . 2 .6`/r . p < 0.0001) .
Hospital nlnrttdiq'rates art, rused srrikingh with lot nnr-
ing age 17ahfe 3 . fig . 4). The mortality rate was relatively
low' until the age of 66 years, when the rate began to increase
markedly . No patient <47 years of age died . The mortality
rate in patients ?75 years was 17 .8% . Age-aJjusted mortal-
ity rates for men and women were not significantly different
(9 .17 vs
. 11
.37 . respectively)
.
Pi a nudtirarinte tenah'sit of odieroe outcome (death,
conge :live heart failure or reinfarcti m) in patients w65 years
of age (1 .836 patients) . adverse en ots were related to two
findings : a previous history of congestive heart failure (odds
ratio 3 .9 : 957 confidence interval 2 .9-5 .2) and increasing
age (odds ratio 1 .4 for each 10-year increment ; 95r/r confi-
dence interval 1 .3-1 .5) . Thrombolytic therapy (given to 12%
of those z65 years) or the use of emergency
(<12
hl
coronary angiography (applied to an additional 10% of those
patients) had no independent salutary effect on mortality
;
however, these procedures and treatments were applied to
only 22 17, of elderly patients and the power for determining a
o25% reduction in adverse outcome was only 45% (two-
sided test : alpha = 0.05) (Table 4) .
Figure 4 . Mortality rates by age for the 3 .216 patients with acute
myocardial infarction . No patient <47 years of age died during
hospitalization . whereas the overall mortality rate in patients 0075
years was 1851
. Gender-specific mortaaly rates were similar in all
but the lust stratum
. The median age of men and women in the group
075 years of age was 80 and 82 years . respectively . Age-adjusted
mortality rotes for men and women were not significantly different
(9.1% and 11 .3%, respectively) .
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Discussion
Elderly patients: who are they? It is commonly acknowl-
edged that thrombolytic therapy reduces the mortality rate in
the elderly . Perhaps this was best shown in a large placebo-
controlled trial (1) of thrombolytic treatment, in which 3,000
patients (9% of all treated) were 0_70 years of age . However .
because no sizable randomized trial has been aimed solely at
the treatment of elderly patients, our understanding of which
patients benefit the most and which are at greatest risk of
serious bleeding. particularly intracranial hemorrhage, is
incomplete
. In this registry, only 5% of patients =_75 years of
age received thrombolytic treatment : thus, it is problematic
to generalize findings in elderly patients treated with throm-
bolytic therapy to the other 95% of the older patient cohort .
The older patients represent a diverse group and the fastest
growing segment of the U .S . population. It has been re-
ported 112) that advanced age is associated with the greatest
potential treatment benefit but also the highest risk of
intracranial bleeding . Thus. it is very important that the
benefits acid risks to specific individuals be better clarified.
The impact of treatment for other manifestations of coronary
heart disease suggests that the effect of thrombolytic ther-
apy . a s well as other acute interventions, may well be
modified by both age and gender . For example, it is known
that the extent of coronary disease and symptoms of angina
increase in severity with advancing age and that drugs used
to treat angina, heart failure and hypertension are less
eMective in this age group. primarily because of the in-
creased incidence of side effects (13-16) . The findings re-
ported here show that older patients mor^ often had a history
of hypertension, congestive heart fai'are and myocardial
infarction and came to the hospital It er than did younger
patients-all important factors [hat could substantially alter
the treatment benefitlrisk ratio .
In addition, half of the elderly group were women,
another group in which the benefits and risks of thrombolytic
therapy have yet to be fully clarified . Some studies (171 have
shown that the outcome for women with acute infarction is
worse than for men. but this may be d ue . at least in part . to
the effect of age . Thus, aside from usual appropriate selec-
lion criteria . the elderly female patient with suspected acute
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presents a situation in which there is relatively
little information to guide a treatment decision .
Factors limiting potential eligibility for .systemic thrombot-
ysis . In an earlier retrospective study of potential eligibility
for thrombolytic therapy. Althouse et al . (18) showed that
after excluding patients for findings associated with an
increased risk of bleeding, long delays before hospital arrival
and nondiagnostic ECG . only 14 of patients -75 sears of
age would otherwise have been candidates for thrombotytic
drug treatment. Low eligibility rates also caused one triad
(19) aimed specifically at treating the elderly to he aborted
for lack of a suitable number of patients .
In our large registry of unselected patients with acute
myocardial infarction, the low rate of treatment (i'iI for
patients w75 years of age suggests that risk factors for poten-
tially serious bleeding . possibly combined with misdiagnosis
anddificulty in physician determination of the risk-benefit ratio
of treatment for individual patients . man well have suited to
hamper the use of thromlrolytic therapy in elderly patients . A
noteworthy factor influencing treatment decisions was the
relatively high proportion of elderly patients who had no chest
pain when first evaluated in the hospital . Second. the preva-
lence of confounding illness associated with a higher potential
risk for serious bleeding increased subsumtially 'with age .
Finally, fewer elderly patients had ST elevation on the initial
ECG . Kudenchuk et al. 1201 showed that even after adjusting
for the presence of prior myocardial infarction in the eldery .
advanced age is less likely to he associated w ith ST segment
elevation. Other studies 12 1) have also shown a greater inci-
dence of non-Q wave infarction in older patients . If more Older
patients are to benefit from thromboltic therapy . there must
be some evidence that this treatment is effective in patients
with other than Q-wave infarction . In total. ._15ry of patients
a75 years of age were potential) suitable candidates for
treatment . This proportion % as three times greater than that
actually treated and. again . probably underlines the difficulty in
assigning benefit and risk of treatment in individual elderly
patients .
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Age . treatment and mortality . It I, clctr from these
oh,enauuns that most patients « ceisIn , thromholstie ther-
apy are relutisaly young and nealthy
. The mortality rate for
patients ~ years of age . of whom ?9'i recetycd throm-
hofytic treatmentL uas onh 2'i, In contrast . 5'i of patients
_ .'s sours otage were treated and the overall mortality rate
for this group was ILB'i . In addition . the use of other
recogni,ed medical treatments as well as coronary proce-
dures was far less common in elderly patients . perhaps as a
result of concern for comorhid conditions that could increase
the risk of ,+d%else effects and complication rues or perhaps
as the result of failure to make a correct diagnosis on
admission to the hospital . The relatively high cardiac dent
rate (death . heart failure and reinfarctionI in the elderl+
cte.oIs show, that interventions could have their greatest
impact in this group: however, the high overall incidence of
stroke 14'71 also highlight, that not all patients should he
treaded in the same was .
Potential role of emergency angiography and mechanical
reperfusiun. Other treatment strategies such as emergency
angiography .intracoronary application ofthrombotytictherc
apy . direct coronary angioplasty and coronary surgery . if
indicated . mat he particularly attractive treatment options in
Older patients . many, of whom are at risk for serious bleeding
complications from thrombotytic therapy . Unfortunately .
there arc no controlled trials examining the effect of such
approaches in elderly high risk patients
. Although angiogra-
phy . angioplasty and surgery were less frequently used in
these patients . the calculated 22'? rate of elective angiogra-
phy was -twice as high in the subset of older patients
without serious comorhid condlt, .,us . : .s we curt-caulk un-
derstand those factors favorably' affecting survival after
acute myocardial infarction, early coronary patenev seems
to he nssociated with the best outcome 11 2_-2_41 . However.
the elderly rim have higher complication rates after invasive
procedures
. which may make an invasive approach less
attractive 1 2_5-2_71. Use of aspirin . heparin, beta-adrenergic
blocking agents and afterload reduction may also he useful
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treatments, providing that they can be safely given without
the complications of bleeding and heart failure, the latter of
which is already evident in >309r of the elderly patients wi!h
acute infarction .
The findings in this contemporary registry of patients
hospitalized with acute myocardial infarction in the greater
metropolitan Seattle area hospitals point out the need to
define effective therapies that can be employed in the major-
ity of patients . The current use of thrombolytic therapy
affects relatively few patients, particularly those in the
elderly age group
.
Conclusion . Few patients s75 years of age are currently
treated with thrombolytic therapy . Preexisting comorbidity .
a greater prevalence of nondiagnostic
ECG
abnormalities,
the absence of chest pain and physicians' concerns about the
benefit/risk ratio in this group are significant contributing
factors . Although these results may not he identical to those
in other cities and countries, we believe that the age-adjusted
findings are typical of those observed anywhere in the
United States. However, the high mortality rates reported in
some placebo-controlled trials of thrombolytic therapy car-
ried out in other countries in which death rates from coro-
nary disease are also known to be higher than the rates
reported here suggest that there may be sociodemographic
differences that could, in turn . affect the age-adjusted mor-
tality rates in these countries .
More needs to be known about the effectiveness of both
pharmacologic and mechanical methods of reperfusion in
older persons and who among the older population benefits
the most with acceptable rates of complication, The utility
and risk of more aggressive r eperfusion methods using either
pharmacologic or mechanical approaches as well as other
medical therapies aimed at reducing the extent of injury and
preventing onset of heart failure need to be defined to
provide the greatest opportunity to the group that can benefit
most .
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